antisens
oligonucleotid
short
interf
rna
sirna
nucleic
acidstarget
reagent
gene
express
modul
develop
drug
mani
applic
number
use
synthet
nucleic
acid
analogu
introduc
recent
greatli
improv
properti
use
therapeut
howev
full
effect
cell
vivo
often
realiz
develop
suitabl
nonvir
deliveri
system
among
rang
natur
synthet
peptid
found
use
enhanc
cellular
uptak
andor
cell
target
oligonucleotid
analogu
sirna
peptid
synthet
conjug
use
noncoval
complex
use
combin
polym
liposom
exosom
formul
techniqu
review
begin
describ
mode
action
antisens
reagent
sirna
goe
focu
recent
advanc
peptidemedi
cell
vivo
deliveri
peptid
use
influenc
drug
develop
review
discuss
challeng
associ
understand
physiolog
toxicolog
aspect
peptidemedi
deliveri
develop
toward
clinic
use
also
highlight
particular
emphasi
peptid
conjug
oligonucleotid
analogu
use
treatment
neuromuscular
diseas
antisens
oligonucleotid
use
wide
interfer
biolog
process
cell
develop
case
drug
numer
type
oligonucleotid
analogu
vari
chemistri
well
short
interf
rna
sirna
encompass
rang
intracellular
target
mode
action
common
oligonucleotid
type
need
deliv
cell
tissu
effici
order
carri
target
function
type
abl
enter
certain
cell
class
vivo
hepatocyt
kidney
cell
reason
effici
nake
form
eg
contain
phosphorothio
ps
linkag
certain
sugar
modif
bioavail
right
cellular
locat
may
still
limit
poor
cell
traffick
endosom
entrap
cell
type
cell
target
entri
found
poor
mani
nake
oligonucleotid
type
abil
reach
desir
tissu
limit
accordingli
massiv
effort
search
new
deliveri
system
may
enhanc
tissu
penetr
improv
cell
target
cell
entri
well
enhanc
intracellular
bioavail
desir
biolog
target
preval
deliveri
system
oligonucleotid
sirna
cation
liposom
nanoparticl
deliveri
system
base
initi
cell
cultur
studi
later
translat
sophist
multicompon
vivo
vector
among
simpler
method
util
enhanc
cell
deliveri
oligonucleotid
sirna
cation
peptid
vector
often
refer
cellpenetr
peptid
cpp
peptid
transduct
domain
ptd
first
cpp
introduc
sinc
continu
stream
new
peptid
deliveri
vector
increas
deliveri
better
pharmacolog
properti
claim
varieti
applic
demonstr
cellular
entri
intracellular
traffick
mechan
behind
peptidemedi
transduct
still
fulli
elucid
review
thoroughli
elsewher
addit
cpp
peptid
design
target
specif
cell
tissu
home
peptid
review
concentr
recent
progress
sinc
variou
peptidemedi
strategi
deliveri
antisens
oligonucleotid
sirna
cell
cultur
also
vivo
applic
point
prospect
clinic
develop
sever
way
short
oligonucleotid
sirna
affect
cellular
process
schemat
illustr
figur
obviou
approach
origin
propos
zamecnik
stevenson
antisens
bind
watsoncrick
base
pair
messeng
rna
mrna
block
translat
initi
elong
thu
decreas
level
correspond
protein
figur
steric
block
ribosom
elong
known
hard
achiev
block
ribosom
initi
effici
target
initi
aug
region
cap
region
appropri
intern
ribosom
entri
site
also
possibl
block
polyadenyl
target
requir
deliveri
oligonucleotid
stoichiometr
amount
target
mrna
present
cell
given
time
steric
block
also
requir
use
strongli
bind
oligonucleotid
analogu
ensur
good
competit
mrna
protein
involv
translat
cellular
process
similarli
stericblock
mrna
bind
oligonucleotid
also
capabl
bind
triplex
mode
certain
specif
dna
sequenc
inhibit
transcript
nucleu
lead
decreas
mrna
product
difficulti
obtain
suffici
potenc
target
chromosom
dna
select
make
gene
express
inhibit
triplex
format
current
less
attract
therapeut
intervent
mechan
howev
sequencespecif
gene
modif
via
triplex
format
new
subject
recent
shown
great
potenti
second
mechan
involv
antisens
bind
rna
follow
recruit
activ
rnaseh
consequ
lead
degrad
mrna
target
figur
mode
action
limit
oligonucleotid
contain
minimum
stretch
unmodifi
dna
ps
dna
unit
known
gapmer
outer
nucleotid
heavili
modifi
enhanc
complementari
rna
bind
principl
catalyt
turnov
allow
lower
concentr
oligonucleotid
use
compar
stericblock
oligonucleotid
rnasehdepend
antisens
use
success
reduc
express
level
specif
protein
inhibit
viral
replic
case
rna
interfer
one
strand
sirna
duplex
antisens
guid
strand
becom
target
mrna
result
recruit
rnainduc
silenc
complex
risc
cellular
machineri
lead
subsequ
rna
cleavag
figur
sirna
target
access
part
mrna
similar
rnasehdepend
oligonucleotid
target
method
sens
passeng
strand
may
includ
chemic
modifi
nucleotid
posit
wherea
antisens
strand
toler
limit
rang
modifi
nucleotid
specif
locat
singlestrand
oligonucleotid
analogu
shown
great
promis
inhibitor
microrna
mirna
action
prevent
mirna
bind
mrna
would
otherwis
trigger
rna
interfer
machineri
result
mrna
downregul
degrad
figur
interestingli
good
level
intracellular
activ
achiev
without
requir
cppassist
deliveri
cell
cultur
vivo
eg
peptid
nucleic
acid
pna
lock
nucleic
acid
lna
contrast
nake
oligonucleotid
target
mrna
high
concentr
extend
period
requir
cell
cultur
rnasehdepend
activ
deliv
gymnot
greek
gymno
mean
nake
oligonucleotid
target
mirna
shown
rapidli
enter
cell
interfer
mirna
activ
submicromolar
concentr
current
think
oligonucleotid
may
meet
mirna
somewher
within
endosom
pathway
therefor
cppenhanc
endosom
releas
may
unnecessari
although
gener
conclus
cell
type
mirna
yet
establish
inhibit
mirna
thought
occur
mirna
sequestr
rather
degrad
therapeut
applic
antimir
recent
review
altern
mechan
also
proven
success
short
oligonucleotid
bind
mrna
cover
mirnabind
site
prevent
risc
bind
subsequ
mrna
downregul
figur
anoth
import
mode
action
antisens
oligonucleotid
involv
splice
redirect
premrna
cell
nucleu
oligonucleotid
direct
region
close
splice
site
mask
normal
aberr
splice
event
lead
either
exon
exclus
figur
exon
inclus
figur
splice
redirect
model
system
use
success
monitor
peptidemedi
oligonucleotid
deliveri
addit
methodolog
alreadi
assess
clinic
treatment
neuromuscular
neurodegen
diseas
target
specif
exon
mutat
dystrophin
premrna
antisens
phosphorodiamid
morpholino
oligonucleotid
pmo
allow
redirect
splice
pattern
restor
correct
read
frame
exon
skip
result
regener
function
dystrophin
protein
express
stimul
exon
inclus
antisens
oligonucleotid
altern
mechan
examin
potenti
treatment
spinal
muscular
atrophi
addit
exon
skip
appli
wildtyp
gene
gener
outoffram
transcript
method
normal
protein
downregul
addit
low
bioavail
poor
stabil
unmodifi
dna
rna
rapid
clearanc
bloodstream
major
drawback
use
therapeut
thu
mani
differ
oligonucleotid
analogu
develop
order
increas
stabil
rna
bind
therapeut
use
properti
select
import
oligonucleotid
analogu
involv
peptidemedi
deliveri
present
figur
analogu
type
particular
properti
make
suitabl
differ
applic
perhap
util
wellstudi
analogu
ps
linkag
sulfur
atom
replac
one
nonbridg
oxygen
atom
phosphat
backbon
figur
ps
linkag
includ
dnaor
rnatyp
oligonucleotid
increas
nucleas
resist
wherea
otherwis
unmodifi
dna
permit
rnaseh
activ
introduct
ps
linkag
reduc
rnatarget
affin
somewhat
lead
enhanc
interact
plasma
protein
therebi
decreas
renal
clearanc
rate
despit
concern
possibl
toxic
side
effect
higher
concentr
ps
linkag
includ
fdaapprov
oligonucleotid
date
unfortun
current
omethyl
nucleotid
ome
methyl
group
replac
hydrogen
atom
hydroxyl
group
ribos
ring
rna
figur
also
impart
nucleas
resist
permit
rnaseh
activ
nonrnaseh
induc
oligonucleotid
enhanc
therapeut
activ
achiev
case
includ
oalkyl
nucleotid
omethoxyethyl
moe
deoxynucleotid
result
mixmer
analogu
also
use
wing
gapmer
well
particular
posit
sirna
highli
success
nucleotid
analogu
lna
constrain
rna
analogu
methylen
bridg
posit
ribos
ring
figur
lna
also
unabl
activ
rnaseh
due
constrain
backbon
lna
high
affin
singlestrand
dna
rna
compar
analogu
addit
high
affin
lna
display
high
vivo
stabil
slower
renal
clearanc
although
rare
case
hepatotox
observ
increas
affin
allow
lna
use
much
shorter
oligonucleotid
mani
analogu
type
tini
lna
howev
nonspecif
bind
longer
sequenc
lna
could
result
offtarget
effect
allevi
use
lna
combin
unmodifi
dna
analogu
ome
stericblock
applic
lna
also
use
rnasehdepend
applic
wing
ps
gapmer
central
section
psdna
separ
class
analogu
charg
neutral
pmo
ribos
replac
morpholino
moieti
natur
phosphodiest
linkag
replac
uncharg
phosphorodiamid
backbon
figur
constrain
structur
lack
electrostat
repuls
oligonucleotid
target
contribut
make
pmorna
interact
stabl
compar
dnarna
interact
pmo
activ
rnaseh
use
success
steric
block
antisens
purpos
mani
vivo
applic
clinic
like
pmo
pna
uncharg
oligonucleotid
analogu
sugarphosph
backbon
replac
repeat
n
glycin
unit
link
togeth
amid
bond
figur
pna
high
affin
dnarna
like
pmo
due
partli
lack
charg
repuls
peptidelik
backbon
pna
display
high
select
mismatch
discrimin
toward
target
strand
use
effect
mani
antisens
applic
vivo
pna
contain
addit
cation
residu
eg
lysin
use
success
block
mirna
activ
without
use
transfect
agent
deliveri
peptid
need
improv
oligonucleotid
therapi
acceler
advanc
chemistri
mani
newer
analogu
emerg
recent
unfortun
abl
attain
high
stabil
affin
select
maintain
low
toxic
offtarget
effect
avail
research
suffici
quantiti
reliabl
vivo
studi
analogu
select
mention
review
attribut
also
util
peptidemedi
deliveri
two
main
way
util
peptid
vector
deliveri
antisens
oligonucleotid
sirna
first
method
involv
chemic
synthesi
peptid
modifi
enabl
coval
conjug
oligonucleotid
cargo
type
figur
conjug
reaction
may
carri
either
solid
support
solut
often
result
high
yield
advantag
coval
conjug
result
welldefin
singl
entiti
simplifi
drug
develop
linker
type
may
chemic
stabl
ensur
peptideoligonucleotid
conjug
remain
intact
throughout
vivo
administr
subsequ
deliveri
process
degrad
reflect
proteolyt
suscept
particular
peptid
numer
conjug
strategi
includ
thioether
thiolmaleimid
ester
format
click
chemistri
review
ref
altern
labil
linker
cleavabl
within
cell
disulphid
linkag
proven
success
studi
peptidemedi
deliveri
cell
vivo
disulphid
bridg
may
remain
suffici
stabl
administr
rapid
may
cleav
later
conjug
reach
reduc
environ
endosom
cytoplasm
approach
initi
favor
therapeut
design
cleavag
diminish
risk
detriment
effect
peptid
interact
oligonucleotid
target
howev
recent
vivo
applic
use
stabl
linkag
suggest
peptidecargo
cleavag
essenti
recent
studi
suggest
also
thiol
disulfid
group
might
enhanc
cellular
uptak
although
reason
yet
fulli
understood
although
coval
conjug
suitabl
chargeneutr
oligonucleotid
analogu
technic
difficulti
conjug
purif
conjug
highli
cation
peptid
neg
charg
oligonucleotid
limit
type
peptid
conjug
sadli
meaning
compar
data
effect
differ
peptideoligonucleotid
linkag
biolog
antisens
assay
mostli
lack
second
method
peptidemedi
oligonucleotid
deliveri
exploit
complex
properti
cpp
deriv
figur
exampl
cation
cpp
form
complex
effici
neg
charg
oligonucleotid
peptid
vector
also
contain
hydrophob
element
hydrophob
amino
acid
addit
hydrophob
amino
acid
andor
moieti
fatti
acid
lipid
cholesterol
design
complex
format
neg
charg
chargeneutr
analogu
type
complex
peptid
form
nanos
particl
togeth
oligonucleotid
better
abl
transloc
across
plasma
membran
case
perhap
avoid
endosom
uptak
system
altogeth
deliv
oligonucleotid
cargo
target
greater
effici
common
optim
empir
ratio
peptid
cargo
obtain
best
cellular
deliveri
noncoval
strategi
requir
oligonucleotid
endmodifi
conjug
thu
complex
format
often
achiev
simpl
mix
complex
format
also
result
protect
oligonucleotid
sirna
nucleas
degrad
hand
structur
vari
undefin
size
may
gener
complic
drug
character
subsequ
vivo
use
case
uncharg
pmo
pna
common
first
hybrid
complementari
dna
strand
leash
complex
format
cation
peptid
vector
recent
new
gener
chemic
modifi
peptid
vector
noncoval
conjug
introduc
figur
base
origin
work
futaki
et
al
involv
stearyl
cation
polyarginin
peptid
deliveri
vector
plasmid
dna
exampl
stearyl
peptid
show
noncoval
complex
format
enhanc
cell
deliveri
ome
spliceredirect
oligonucleotid
seem
peptid
sequenc
need
care
tune
type
cargo
well
applic
sinc
exampl
stearyl
polyarginin
peptid
found
ineffect
cellular
deliveri
splicecorrect
oligonucleotid
despit
effect
larger
plasmid
nanovector
involv
peptid
associ
cation
polym
figur
peptid
complexedcel
surfac
display
liposom
exosom
figur
addit
cpp
design
gener
enhanc
cell
entri
peptid
also
use
target
specif
cell
surfac
receptor
tissu
home
peptid
conjug
oligonucleotid
figur
incorpor
chimera
cpp
embed
surfac
nanovector
figur
last
concept
combin
cellpenetr
celltarget
properti
peptid
oligonucleotid
sirna
encapsul
technolog
eg
liposom
exosom
recent
open
new
possibl
cell
deliveri
type
deliveri
agent
advantag
gain
nake
oligonucleotid
sirna
use
peptid
vector
whether
conjug
complex
enhanc
cell
andor
vivo
deliveri
must
outweigh
disadvantag
addit
size
molecul
increas
potenti
cost
per
gram
case
sirna
except
kidney
topic
applic
clear
complex
vector
sort
requir
obtain
signific
vivo
activ
partli
vector
protect
sirna
rapid
degrad
well
help
sirna
passag
cell
releas
endosom
simpl
peptidebas
complex
vector
attract
compar
better
known
complex
lipidbas
polymer
nanoparticl
vector
term
simplic
cost
compon
question
whether
peptid
vector
found
offer
suffici
vivo
deliveri
power
tissu
target
compar
sophist
type
deliveri
vector
contrast
case
oligonucleotid
advantag
use
peptid
vector
fulli
depend
organ
type
applic
liver
vivo
applic
exampl
alreadi
good
deliveri
nake
ps
oligonucleotid
peptid
vector
seem
unlik
add
margin
benefit
best
howev
deliveri
muscl
exampl
nake
oligonucleotid
analogu
includ
pmo
pna
requir
high
dosag
anim
obtain
activ
see
exampl
muscular
dystrophi
applic
describ
later
substanti
improv
vivo
activ
afford
coval
peptid
conjug
easili
outweigh
ad
cost
effort
conjug
exampl
follow
reader
bear
mind
still
rel
peptid
vector
current
consid
therapeut
use
public
address
toxicolog
potenti
immun
recognit
demonstr
cost
benefit
analysi
vector
describ
enhanc
cell
deliveri
repres
therefor
research
progress
peptidemedi
deliveri
rnasehdepend
antisens
oligonucleotid
cell
cultur
first
shown
coval
cpp
conjug
coval
cpp
attach
concept
later
use
stericblock
pna
downregul
galanin
receptor
vivo
sinc
mani
demonstr
antisens
sirna
cell
deliveri
cpp
publish
tabl
show
recent
exampl
choic
antisens
mechan
sirna
depend
particular
applic
turn
influenc
type
peptid
deliveri
system
avail
case
particular
rna
target
permit
choic
target
method
avail
gener
lower
potenc
stericblock
oligonucleotid
balanc
greater
possibl
offtarget
effect
rnasehdepend
riscdepend
activ
effect
may
aris
exampl
bind
oligonucleotid
incorrect
target
sequenc
result
unwant
rna
cleavag
mirnalik
effect
sirna
passeng
strand
cellular
effect
immun
activ
peptidemedi
deliveri
often
result
rais
level
cellular
activ
could
also
lead
increas
offtarget
effect
compar
use
cation
liposom
enhanc
deliveri
suffer
problem
wherea
potenc
increas
frequent
demonstr
offtarget
effect
rare
measur
systemat
peptid
vector
use
common
find
simpl
cell
toxic
assay
carri
limit
abil
compar
method
effect
recent
exampl
peptid
conjug
oligonucleotid
use
target
mrna
tabl
varieti
cpp
cation
amphipath
origin
disulfideconjug
pna
target
nociceptinorphanin
fq
receptor
mrna
studi
receptor
downregul
cardiomyocyt
among
cpp
repeat
kla
amphipath
peptid
found
highest
activ
pna
conjug
absenc
transfect
agent
comparison
made
argrich
peptid
interestingli
found
correl
bioactiv
level
fluoresc
uptak
label
conjug
confirm
previou
studi
peptidepna
receptor
downregul
improv
cpp
conjug
rel
modest
amount
signific
phenotyp
activ
nake
pna
lack
clear
quantit
link
phenotyp
genotyp
antisens
activ
call
question
extent
mrna
antisens
behavior
truli
observ
model
perhap
promis
exampl
mrna
target
involv
rnasehdepend
gapmer
oligonucleotid
target
transcript
factor
coupl
peptid
fragment
high
mobil
group
protein
home
neovessel
xenograft
tumor
conjug
show
substanti
inhibit
tumor
growth
metastasi
mous
tumor
xenograft
model
peptid
shown
bind
nucleolin
overexpress
surfac
cancer
cell
subsequ
transport
nucleu
like
cation
natur
peptid
may
result
aggreg
conjug
form
nanoparticl
solut
lead
partial
protect
degrad
serum
perhap
improv
cell
vivo
activ
although
deliveri
oligonucleotid
conjug
home
peptid
tumor
endothelium
dosedepend
tabl
select
peptid
oligonucleotid
conjug
complex
use
anti
gene
target
protein
knockdown
observ
cell
vivo
surprisingli
sequenceand
dosedepend
downregul
correspond
mrna
report
thu
remain
question
whether
biolog
activ
observ
fulli
due
sequencespecif
antisens
effect
studi
nevertheless
strong
vivo
activ
observ
undeni
among
peptidecomplex
deliveri
strategi
pegyl
amphipath
peptid
shown
mediat
vivo
deliveri
pna
analogu
oligonucleotid
target
cyclin
mrna
follow
intraven
inject
format
nanoparticl
result
reduct
rate
tumor
growth
short
peptid
combin
lysineargininerich
hydrophil
domain
tryptophanphenylalanin
hydrophob
residu
form
stabl
complex
antisens
oligonucleotid
pegyl
necessari
vivo
activ
case
effect
steric
block
target
close
aug
start
sequenc
sequenceand
dosedepend
well
valid
excess
oligom
need
optim
cell
deliveri
wherea
vivo
layer
pegyl
peptid
ad
initi
complex
unmodifi
peptid
enhanc
deliveri
pep
deriv
develop
sirna
see
splice
redirect
use
extens
measur
efficaci
peptidemedi
cell
deliveri
oligonucleotid
due
conveni
readout
system
hela
cell
stabli
transfect
luciferas
gene
interrupt
mutat
globin
intron
mutat
caus
aberr
splice
luciferas
premrna
thu
prevent
translat
oligonucleotid
target
particular
sequenc
close
aberr
splice
site
eg
site
induc
correct
splice
thu
restor
luciferas
activ
similar
construct
involv
use
green
fluoresc
protein
gfp
place
luciferas
reliabl
posit
readout
larg
dynam
rang
method
allow
efficaci
differ
peptid
vector
conjug
strategi
analogu
type
compar
assay
well
valid
mani
analogu
type
deliveri
method
sequencespecif
doubt
studi
hela
assay
serv
model
system
help
elucid
cellular
uptak
mechan
gener
cpp
conjug
deliv
endocytosi
cpp
believ
help
releas
endosom
uptak
mechan
peptidecomplex
oligonucleotid
appear
divers
peptid
complex
agent
mpg
appear
util
endocytosi
wherea
similar
peptid
nonenergydepend
membranecross
pathway
propos
obtain
splice
redirect
oligonucleotid
must
deliv
cell
nucleu
debat
continu
whether
endocytosi
energyindepend
mechan
deliveri
optim
applic
term
bioavail
known
poorli
correl
cell
uptak
recent
studi
conjug
chargeneutr
antisens
pna
pmo
earlier
penetratin
tat
transduct
domain
replac
argrich
cpp
tabl
paradigm
peptid
arg
residu
space
aminohexanoyl
ahx
x
andor
alanyl
moieti
enhanc
hydrophob
proteolyt
resist
serum
rahxr
ahxala
rahxrralar
ahxala
call
bpeptid
respect
aminohexanoyl
spacer
rahxr
motif
found
optim
splicingredirect
assay
among
sever
spacer
tri
base
initi
discoveri
addit
six
arg
residu
penetratin
peptid
result
significantli
enhanc
splice
redirect
pna
hela
cell
seri
peptid
known
pip
pna
pmo
intern
peptid
develop
includ
hydrophob
core
flank
two
argrich
region
attach
pna
maintain
good
splice
redirect
submicromolar
concentr
yet
serum
stabl
therefor
usabl
vivo
anoth
recent
idea
add
second
chemic
moieti
fatti
acid
end
argrich
peptid
enhanc
deliveri
pna
conjug
found
decano
acid
optim
chain
length
balanc
increas
splice
redirect
obtain
concurr
increas
cell
toxic
chain
length
extend
separ
studi
addit
palmitoyl
lipid
chain
free
terminu
pna
r
pna
conjug
also
increas
spliceredirect
activ
suggest
increas
activ
due
micel
format
conjug
omep
antisens
oligonucleotid
bival
rgd
peptid
select
target
v
integrin
found
enter
cell
via
receptormedi
endocytosi
use
splice
redirect
melanoma
cell
rgd
conjug
found
enter
cell
endocytot
pathway
distinct
nake
oligonucleotid
recent
spliceredirect
antisens
oligonucleotid
conjug
bombesin
peptid
intracellular
deliveri
studi
gastrinreleas
peptid
receptor
express
cell
transfect
luciferas
gene
interrupt
abnorm
splice
intron
result
suggest
conjug
enter
cell
via
process
gastrinreleas
peptid
receptormedi
endocytosi
follow
traffick
deep
endomembran
compart
lead
significantli
higher
luciferas
express
compar
unmodifi
oligonucleotid
principl
use
peptid
target
cell
surfac
receptor
particularli
overexpress
marker
cancer
cell
excel
one
issu
lie
whether
suffici
molecular
recognit
peptid
conjug
individu
oligonucleotid
deliv
enough
specif
receptormedi
endocytot
pathway
provid
larg
boost
splice
redirect
relev
vivo
set
demonstr
quantit
use
peptidemedi
deliveri
cell
vivo
await
eagerli
variou
type
stearyl
peptid
use
aid
redirect
splice
use
noncoval
strategi
peptid
ratio
compar
omep
oligonucleotid
much
effect
luciferas
upregul
stearylarg
hela
cell
effort
gone
develop
stearyl
deriv
peptid
transportan
nucleic
acid
deliveri
agent
gener
class
stearyl
peptid
deliveri
agent
seem
util
endocytot
pathway
peptid
deriv
contain
pair
ornithin
well
pair
leucin
residu
show
particularli
good
splice
redirect
omep
oligonucleotid
hela
cell
assay
well
exon
skip
mous
mdx
muscl
cell
cppaid
splice
redirect
also
promis
mechan
vivo
therapeut
applic
mdx
mous
model
duchenn
muscular
dystrophi
dmd
bear
nonsens
mutat
exon
dystrophin
gene
import
vivo
system
evalu
peptidedeliveri
method
exon
skip
oligonucleotid
analogu
target
exon
restor
transcript
read
frame
henc
product
shorter
activ
dystrophin
protein
bpmo
conjug
show
dramat
improv
dystrophin
product
compar
nake
pmo
follow
intraven
inject
mdx
mous
pmo
conjug
chimer
cpp
compris
bpeptid
short
musclespecif
peptid
known
bmsp
show
higher
activ
skelet
tissu
mdx
mice
bpmo
improv
pip
seri
argrich
peptid
conjug
pmo
show
enhanc
dystrophin
product
skelet
muscl
heart
use
singl
mgkg
inject
signific
develop
togeth
respiratori
difficulti
cardiac
deterior
major
caus
death
dmd
patient
peptidepna
conjug
also
use
vivo
antisens
studi
target
dmd
well
target
exampl
report
recent
amphipath
peptid
coval
conjug
pna
abl
redirect
splice
murin
pten
primari
transcript
adipos
tissu
male
balbc
mice
lowdos
intraperiton
inject
mgkg
studi
show
clear
depend
level
pna
antisens
activ
adipos
tissu
depend
peptid
carrier
sequenc
enhanc
splice
redirect
pna
pmo
clearli
wellsuit
applic
coval
attach
cpp
potenti
peptid
type
peptid
vector
develop
like
neg
charg
splicedirect
oligonucleotid
good
cell
deliveri
enhanc
observ
sever
case
complex
peptid
vector
yet
translat
suffici
advantag
vivo
nake
oligonucleotid
cautionari
tale
serv
remind
introntarget
lead
clear
interpret
observ
biolog
activ
exampl
pna
target
intron
sequenc
sever
combin
immunodefici
mous
model
burkitt
lymphoma
conjug
lysrich
nuclear
local
signal
peptid
shown
effect
block
tumor
growth
multipl
intraven
inject
surpris
result
lysrich
peptid
like
degrad
rapidli
circul
thu
insuffici
intact
act
nuclear
local
signal
peptid
conjug
may
instead
alter
bioavail
pna
peptid
conjug
examin
mechan
action
pna
case
obscur
pna
target
e
enhanc
sequenc
regul
cmyc
overexpress
pna
bind
may
perhap
alter
rna
secondari
structur
downregul
cmyc
express
rather
alter
splice
pattern
three
recent
exampl
antigen
pna
agpna
target
describ
tabl
agpna
conjug
lysrich
argrich
short
peptid
shown
effect
target
progesteron
receptor
promot
dna
breast
cancer
cell
result
downregul
receptor
protein
product
achiev
activ
cell
need
treat
concentr
agpna
sever
day
clear
whether
target
truli
obtain
dna
level
instead
short
rna
deriv
transcript
promot
site
perhap
promis
target
pna
conjug
peptid
ly
repeat
cag
sequenc
mrna
huntingtin
block
mutant
express
select
cell
would
potenti
approach
treat
huntington
diseas
howev
altern
promis
method
target
announc
laboratori
involv
use
oligonucleotid
analogu
sirna
mirna
mimic
may
turn
higher
alleleselect
vivo
studi
await
eagerli
interest
new
applic
use
triplexform
pna
conjug
classic
cpp
penetratin
direct
gene
modif
hematopoiet
stem
cell
mice
retain
unmodifi
differenti
capabl
sequencespecif
gene
modif
also
observ
multipl
somat
tissu
follow
system
administr
also
preserv
bone
marrow
spleen
recipi
mice
follow
transplant
bone
marrow
penetratinpnatr
mice
suggest
peptidepna
conjug
might
good
potenti
applic
treatment
monogen
hematolog
diseas
thalassemia
sickl
cell
anemia
antimir
oligonucleotid
type
util
ome
lna
fluoro
analogu
usual
mixmer
one
analogu
type
dna
tabl
vivo
applic
util
ps
linkag
current
paper
describ
peptid
deliveri
antimir
discuss
seem
nake
oligonucleotid
analogu
may
abil
enter
cell
endocystosi
also
effici
block
mirna
activ
without
need
enhanc
transfect
peptid
vector
thu
seem
unlik
peptidemedi
deliveri
valu
oligonucleotid
type
case
pna
antimir
ad
ly
residu
enhanc
cell
uptak
significantli
termin
cy
residu
also
add
uptak
potenti
antimir
activ
longer
peptid
requir
activ
conjug
argrich
tat
peptid
pna
antimir
also
shown
effici
cell
deliveri
maintain
mirna
regul
activ
cell
cultur
addit
cpp
seem
like
cpp
would
worth
investig
futur
develop
pna
antimir
target
specif
tissu
type
cancer
cell
coval
conjug
sirna
cpp
met
limit
success
tabl
exampl
reduct
mrna
express
achiev
high
concentr
cpp
tat
penetratin
conjug
end
sens
strand
sirna
appropri
posit
conjug
interest
peptid
conjug
recent
way
cell
skin
penetr
peptid
call
space
identifi
phage
display
techniqu
evalu
deliveri
sirna
vivo
two
differ
target
gapdh
mrna
conjug
sirna
space
peptid
led
enhanc
skinabsorpt
properti
knockdown
correspond
protein
target
hope
use
conjug
treat
atop
dermat
unfortun
experi
describ
show
knockdown
mrna
level
requir
sure
effect
observ
cell
mice
protein
reduct
entir
due
sirnadirect
rna
cleavag
cyclic
rgd
peptid
investig
triand
tetraval
conjug
sirna
shown
bring
dosedepend
reduct
report
luciferas
express
human
melanoma
cell
monoval
dival
conjug
result
demonstr
oligonucleotid
multival
like
necessari
conjug
sirna
suffici
effect
celltarget
approach
gener
noncoval
complex
format
fruit
strategi
sirna
deliveri
tabl
amphipath
cholesterolfunction
peptid
carrier
shown
capabl
complex
sirnatarget
cyclin
lead
tumor
growth
reduct
intraven
inject
cancer
model
high
stabil
nanoparticl
slow
releas
sirna
within
cell
allow
use
low
concentr
sirna
peptid
name
cadi
also
report
research
group
bring
inhibit
tumor
growth
complex
sirna
cadi
adopt
helic
conform
within
cell
membran
charg
amino
acid
expos
one
side
helix
tryptophan
residu
found
essenti
good
cellular
uptak
side
importantli
cadysirna
complex
shown
bind
phospholipid
biolog
membran
via
electrostat
interact
enter
cell
energyindepend
transloc
therebi
bypass
endosom
pathway
fusion
peptid
tat
membran
lytic
peptid
shown
form
complex
short
hairpin
rna
sirna
target
bcrabl
oncoprotein
mrna
short
hairpin
rna
induc
stabl
silenc
gene
target
chronic
myeloid
leukemia
cell
compar
sirna
complex
stearyl
peptid
vector
also
use
success
deliv
sirna
lipopeptid
design
aid
endosom
releas
attach
four
ph
titrat
trifluoromethylquinolin
moieti
lysin
side
chain
shown
form
nanoparticl
sirna
knockdown
mrna
product
rang
cell
type
well
kidney
lung
liver
mice
upon
tail
vein
infus
mgkg
altern
peptidesirna
complex
approach
util
recombin
fusion
hiv
tat
protein
ptd
doublestrand
rna
bind
domain
drbd
bind
sirna
neutral
neg
charg
ptddrbd
peptid
vector
shown
excel
cellular
deliveri
sirna
variou
primari
transform
cell
ptddrbd
use
packag
two
sirna
simultan
egfr
induc
tumorspecif
apoptosi
glioblastoma
model
intracerebr
inject
also
substanti
increas
mous
surviv
ptddrbd
peptid
develop
industri
larg
size
make
unsuit
chemic
synthesi
gener
applic
sirna
deliveri
vivo
especi
system
use
doubt
absenc
exampl
efficaci
although
exampl
peptid
use
deliveri
neg
charg
oligonucleotid
antivir
agent
peptid
conjug
chargeneutr
pna
pmo
investig
year
peptidepmo
antivir
applic
includ
target
dengu
viru
cocksackieviru
ebola
marburg
virus
exampl
review
refer
despit
reassur
result
pnapeptid
target
transactiv
respons
element
nontox
mice
high
mg
kg
dose
antivir
develop
seem
recent
ceas
pna
peptid
contrast
bpeptid
conjug
pmo
oligonucleotid
recent
shown
high
antivir
activ
cell
cultur
vivo
variou
system
tabl
exampl
ppmo
conjug
interf
splice
hemagglutininactiv
proteas
premrna
suppress
viral
titer
two
three
log
unit
influenza
cultur
similarli
block
viral
replic
human
respiratori
syncyti
virus
cell
balbc
mice
pmo
sequenc
target
start
code
region
interestingli
also
reduct
lung
viral
titer
even
treatment
mice
hour
infect
hour
infect
suggest
pmo
need
present
cell
soon
infect
impact
viru
product
particularli
promis
result
obtain
vivo
preand
postinfect
ppmo
treatment
pig
infect
porcin
reproduct
respiratori
syndrom
viru
reduc
viremia
interstiti
pneumonia
conjug
also
seen
substanti
improv
antisens
activ
vivo
nake
pmo
protect
mice
upon
infect
west
nile
viru
coronaviru
target
specif
viral
rna
site
involv
translat
replic
overal
ppmo
approach
promis
also
must
compet
antivir
approach
includ
use
pmo
analogu
cation
group
within
pmo
current
exploit
avi
biopharma
bothel
wa
increas
multidrug
resist
bacteria
difficulti
discoveri
new
small
molecul
antibiot
prompt
consider
new
strategi
gene
target
pna
pmo
treat
bacteri
diseas
howev
deliveri
pna
bacteri
cell
prove
problemat
although
cpp
may
intrins
antimicrobi
activ
peptidemedi
deliveri
antisens
pna
pmo
target
specif
essenti
bacteri
gene
suggest
year
use
peptidepna
conjug
shown
recent
promis
antibacteri
strategi
tabl
particular
argrich
peptid
conjug
pmo
abl
penetr
cell
outer
membran
display
genespecif
antibiot
activ
gramneg
bacteria
peptidepmo
conjug
abl
reduc
bacteri
blood
titer
increas
surviv
escherichia
coli
infect
mice
recent
novel
argrich
peptid
deriv
human
cell
conjug
pmo
target
gyra
abl
induc
broad
rang
bacteri
cell
kill
concentr
much
lower
requir
activ
argrich
peptidepmo
higher
perhap
anticip
activ
attribut
nongenespecif
rna
target
ppmo
addit
gene
specif
effect
suggest
partial
bacteriocid
activ
play
import
role
interestingli
pmo
contain
posit
charg
pmo
backbon
also
antisens
activ
achiev
effici
peptideconjug
pmo
pna
conjug
lysrich
peptid
also
use
success
valid
essenti
gene
target
escherichia
coli
studi
relationship
decreas
mrna
express
growth
rate
declin
peptideconjug
pna
target
rpod
gene
essenti
bacteri
growth
show
broad
inhibit
multidrugresist
escherichia
coli
salmonella
enterica
klebsiella
pneumonia
shigella
flexneri
cell
vivo
varieti
recent
promis
result
show
peptidemedi
deliveri
pmo
pna
hold
promis
drug
develop
multidrugresist
bacteria
synthet
natur
occur
cation
polym
repres
larg
group
carrier
nucleic
acid
although
initi
develop
purpos
gene
deliveri
numer
report
affirm
util
oligonucleotid
deliveri
linear
branch
polym
rang
first
discov
polyllysin
pll
frequent
use
polyethyleneimin
pei
share
properti
condens
oligonucleotid
small
particl
polyplex
facilit
cellular
uptak
via
endocytosi
howev
deliveri
effici
toxic
vari
significantli
pei
produc
particular
assort
structur
variant
major
drawback
use
pei
mani
cation
polym
nonbiodegrad
natur
rais
toxic
concern
furthermor
effici
poor
vivo
mani
case
due
unwant
interact
serum
compon
polyethylen
glycol
peg
linker
differ
size
includ
pei
polym
order
prolong
circul
time
blood
review
ref
although
pegyl
significantli
stabil
polyplex
unfortun
often
result
lower
potenc
due
inadequ
cellular
uptak
poor
endosom
escap
anoth
strategi
stabil
polyplex
involv
use
hydrophob
modif
exampl
partial
modif
amin
pei
tyrosin
stabil
polyplex
significantli
increas
transfect
sirna
spliceredirect
ome
oligonucleotid
analog
modif
polyamin
hydrophob
acryl
result
stabil
core
highli
effici
sirna
ome
antimir
deliveri
vivo
peptid
modif
cation
polym
use
success
either
improv
tissu
target
overal
deliveri
efficaci
decreas
requir
dose
pioneer
work
laboratori
ernst
wagner
show
peimedi
gene
transfer
improv
dramat
incorpor
receptortarget
peptid
ligand
review
ref
mani
group
capit
peptidecation
polym
strategi
improv
gene
deliveri
profoundli
surprisingli
exampl
use
target
peptid
cpp
enhanc
polyplex
deliveri
oligonucleotid
spars
one
studi
tat
peptid
conjug
pegyl
pei
complex
ome
oligom
inject
intramuscularli
mdx
mice
improv
exon
skip
dystrophin
premrna
sever
success
studi
sirna
deliveri
report
schiffel
et
al
util
integrinbind
peptid
rgd
attach
pegyl
pei
deliveri
sirna
target
vegfr
tumorbear
mice
similarli
wang
et
al
conjug
bombesin
peptid
via
peg
spacer
free
thiol
group
amphiphil
polym
n
iminobi
n
propionamid
ehco
target
bombesin
receptor
overexpress
variou
cancer
cell
sirna
function
polym
complex
shown
effici
promot
rna
interfer
respons
cell
system
administr
sirna
bombesincontain
ehco
display
signific
advantag
nontarget
polym
induc
target
reduct
xenograft
model
human
glioma
pegyl
transferrin
peptid
combin
oligoethyleneimin
abl
deliv
sirna
highli
effici
neuroblastomabear
mice
eleg
demonstr
receptorspecif
uptak
defin
folatepegsirna
conjug
togeth
structur
defin
polyc
shown
use
complex
specif
gene
silenc
instead
target
peptid
wagner
group
obtain
improv
endosom
escap
inclus
fusogen
peptid
initi
studi
pegyl
polylysinepei
coval
link
endosomolyt
peptid
melittin
sinc
melittin
possess
lytic
properti
neutral
low
ph
amin
within
peptid
mask
reaction
dimethylmal
anhydrid
dmma
dimethylmal
group
remov
low
ph
within
endosom
thu
expos
lytic
peptid
polycationpegdmmamelittin
conjug
mix
sirna
form
polyplex
effici
induc
rna
interferen
respons
cell
cultur
studi
compon
cystein
residu
incorpor
pll
allow
disulfid
format
sirna
contain
thiolat
sens
strand
conjug
almost
effici
polyplex
display
reduc
cytotox
anoth
import
exampl
peptidepolym
combin
cyclodextrin
contain
polym
cdp
base
system
far
platform
report
rna
interfer
deliveri
human
cdp
short
polyc
assembl
nucleic
acid
eg
sirna
via
electrostat
interact
order
facilit
endosom
escap
imidazol
group
incorpor
end
polym
act
proton
spong
system
deliveri
polym
stabil
inclus
surfacefunction
peg
moieti
contrast
polymer
deliveri
system
cdp
approach
reli
noncoval
incorpor
peg
via
conjug
adamantan
small
molecul
form
high
affin
inclus
complex
cyclodextrin
final
order
confer
tissu
target
solid
tumor
surfac
cdp
coat
adamantan
conjug
transferrin
ligand
target
transferrin
receptor
express
abundantli
surfac
tumor
mani
common
cation
liposom
vector
use
nucleic
acid
deliveri
cell
cultur
lipofectin
lipofectamin
suit
vivo
use
sensit
serum
protein
toxic
surfac
function
inert
hydrophil
polym
peg
improv
vivo
use
vector
review
ref
pegyl
decreas
cell
deliveri
due
poor
membran
interact
poor
endosom
escap
new
lipid
formul
includ
peptid
broaden
repertoir
liposom
use
oligonucleotid
deliveri
particular
inclus
argrich
cpp
liposom
proven
potent
strategi
enhanc
transfect
recent
exampl
peptidemedi
sirna
deliveri
liposom
nanoparticl
octaargininemodifi
use
encapsul
sirna
silenc
endogen
gene
liver
cell
well
vivo
low
concentr
sirna
use
singl
dose
without
evid
liver
toxic
anoth
exampl
cation
liposom
modifi
chimer
peptid
contain
lysin
residu
short
multicel
target
peptid
use
deliv
sirna
luciferas
gapdh
target
exampl
ration
liposom
design
multifunct
envelopetyp
devic
mend
system
prototyp
mend
oligonucleotid
condens
polyc
protamin
wrap
lipid
envelop
contain
cation
anion
helper
lipid
dope
improv
endosom
escap
addit
surfac
modif
peg
peptid
deliveri
vector
incorpor
surfac
liposom
use
stearyl
peptid
spontan
insert
lipid
membran
novel
version
mend
contain
cleavabl
peg
linker
well
target
peptid
specif
receptor
fusogen
peptid
order
confer
target
specif
tissu
control
releas
encapsul
cargo
review
ref
mend
effici
exploit
deliveri
unmodifi
singlestrand
antisens
oligonucleotid
cell
well
sirna
cell
ex
vivo
dendrit
cell
recent
even
sophist
mend
system
effici
util
system
target
deliveri
sirna
tumor
similar
liposom
deliveri
system
develop
drug
deliveri
torchillin
colleagu
surfac
decor
cpp
tat
incorpor
tat
peptid
control
manner
coval
link
anion
lipid
phosphatid
acid
spontan
insert
liposom
liposom
use
primarili
target
deliveri
plasmid
dna
tumor
also
shown
effect
sirna
deliveri
cpp
also
use
conjunct
convent
liposomebas
transfect
agent
synergist
effect
report
deliveri
splice
redirect
ome
oligom
practic
nanoparticl
vector
oligonucleotid
deliveri
develop
target
liver
tumor
develop
effici
carrier
cross
biolog
barrier
bloodbrain
barrier
infanc
addit
synthet
nonvir
vector
still
retain
inher
risk
rais
immun
respons
caus
system
toxic
vivo
altern
biolog
deriv
vector
recent
propos
make
use
natur
occur
membran
vesicl
secret
cell
found
bodi
fluid
thought
key
mediat
inform
transmiss
cell
bodi
subgroup
vesicl
term
exosom
shown
recent
contain
variou
rna
speci
exert
biolog
effect
either
directli
activ
cell
surfac
receptor
target
cell
transfer
protein
cell
origin
recipi
furthermor
numer
studi
suggest
exosom
deriv
endolysosom
pathway
diamet
nm
play
crucial
role
horizont
transfer
rna
neighbor
distant
recipi
cell
particular
interest
abil
deliv
mirna
recipi
cell
induc
gene
silenc
properti
indic
would
highli
suitabl
candid
oligonucleotid
sirna
deliveri
wood
et
al
recent
provid
first
proofofconcept
studi
deliveri
exogen
sirna
use
exosom
immatur
dendrit
cell
chosen
sourc
exosom
lack
tcell
activ
thu
immunolog
inert
order
confer
target
exosom
brain
dendrit
cell
transfect
plasmid
express
exosom
protein
fuse
brainspecif
peptid
rabi
viru
glycoproteinderiv
peptid
rvg
becom
present
surfac
exosom
rvgtarget
exosom
subsequ
purifi
cell
cultur
load
exogen
sirna
electropor
system
deliveri
gapdh
target
sirna
rvgexosom
result
specif
knockdown
gapdh
sever
region
mous
brain
cortex
striatum
potenc
rvgexosom
test
deliveri
sirna
target
enzym
secretas
result
signific
specif
target
knockdown
mous
brain
cortex
knockdown
led
reduct
extracellular
accumul
toxic
amyloid
speci
produc
implic
caus
alzheim
diseas
toxic
immunogen
observ
even
repeat
administr
prerequisit
mani
diseas
applic
crucial
clinic
applic
peptidebas
oligonucleotid
sirna
therapi
tailor
drug
wholebodi
distribut
order
maxim
specif
tissu
target
minim
induc
toxic
immun
respons
vivo
biodistribut
data
deriv
either
assess
induc
biolog
affect
detect
directli
label
biocargo
use
transgen
anim
report
system
yet
method
caveat
use
measur
induc
biolog
affect
restrict
tissu
transcript
target
oligonucleotid
sirna
express
exampl
use
dystrophin
exon
skip
protein
restor
readout
mdx
mous
model
fluoresc
molecul
radioact
isotop
use
success
label
follow
biodistribut
peptid
conjug
biocargo
pna
howev
import
note
peptid
part
label
label
detect
may
alway
correl
locat
bioactiv
cargo
exampl
recent
report
ntermin
fitclabel
bpmo
cross
bloodbrain
barrier
reach
purkinj
cell
wildtyp
mice
view
caution
confirm
method
transgen
mous
model
ubiquit
express
aberrantli
splice
premrna
report
gene
use
assess
function
biodistribut
bpmo
howev
distribut
assess
might
reflect
potenti
peptidepmo
influenc
diseas
patholog
wherea
anim
model
diseas
dmd
becom
less
issu
nevertheless
use
three
techniqu
togeth
provid
valuabl
inform
build
view
peptid
affect
biodistribut
oligonucleotid
cargo
import
paramet
system
deliveri
rout
administr
ie
intraven
intraperiton
subcutan
oral
nasal
order
find
best
biodistribut
pattern
particular
applic
also
obtain
optim
safeti
profil
efficaci
deliveri
rout
depend
specif
peptid
ligand
well
celltarget
requir
studi
diseas
must
balanc
toxicolog
profil
peptidemodifi
cargo
direct
comparison
deliveri
rout
publish
bpmo
conjug
exampl
higher
effici
achiev
via
intraven
deliveri
rout
compar
subcutan
rout
toxic
unwant
immun
activ
peptid
conjug
oligonucleotid
sirna
need
care
assess
case
exampl
penetratinsirna
conjug
show
innat
immun
activ
follow
intratrach
administr
contrast
penetratinpna
conjug
induc
immunogen
respons
intraperiton
deliveri
well
toler
mice
mgkg
although
cpp
potenti
stimul
unwant
immunolog
respons
small
size
use
analogu
reduc
risk
significantli
exampl
immun
respons
seen
date
b
peptidepmo
report
peptidepmo
peptidepna
conjug
date
induc
signific
respons
natur
level
vivo
toxic
current
well
understood
peptid
conjug
oligonucleotid
peptidebas
vector
deliveri
rout
publish
vivo
studi
probabl
commerci
sensit
data
howev
peptidepmo
act
good
case
studi
pmo
cargo
amazingli
good
safeti
profil
anim
mani
clinic
trial
thu
safeti
profil
ppmo
conjug
depend
almost
entir
upon
specif
peptid
sequenc
assess
context
therapeut
dose
requir
particular
clinic
set
amantana
et
al
investig
safeti
profil
rat
anticmyc
pmo
conjug
cpp
although
lower
dose
cpppmo
well
toler
mgkg
advers
event
lethargi
weight
loss
elev
blood
urea
nitrogen
serum
creatinin
level
report
much
higher
dose
mgkg
lethal
dose
report
mgkg
toxic
also
report
nonhuman
primat
follow
preclin
studi
bpmo
peptid
conjug
develop
avi
biopharma
dosedepend
toxic
observ
healthi
cynomolgu
monkey
four
weekli
intraven
inject
mgkg
caus
tubular
degener
kidney
avi
biopharma
websit
wwwaviobiocom
toxic
effect
observ
higher
dose
mdx
mice
thu
highlight
ppmo
toxic
threshold
vari
speci
although
lower
toxic
threshold
report
elsewher
comparison
studi
assess
use
cpp
deliv
nonoligom
problemat
effect
cargo
distinguish
cpp
anoth
use
studi
wancewicz
et
al
report
acut
toxic
mice
pna
contain
nine
addit
ly
residu
dose
three
time
week
week
similarli
pna
conjug
amphipath
peptid
contain
ly
leu
ala
residu
show
sever
nephrotoxoc
profound
proxim
tubul
necrosi
mgkg
dose
wherea
pna
conjug
mostli
arg
homoarg
residu
show
toxic
dose
interestingli
tissu
distribut
two
peptidepna
differ
wide
latter
argrich
conjug
show
good
splice
redirect
adipos
tissu
target
organ
even
low
dose
mgkg
thu
although
immunogen
seem
unlik
issu
small
peptid
oligonucleotid
conjug
toxic
profil
need
evalu
care
case
case
basi
establish
effect
yet
safe
dose
regimen
human
clearli
import
need
determin
exact
natur
peptideinduc
toxic
pattern
alongsid
develop
peptid
modif
peptid
applic
reach
clinic
effort
translat
synthet
peptid
conjug
complex
oligonucleotid
sirna
treat
human
diseas
recent
step
mani
polymer
liposom
nanovector
involv
peptid
shown
great
promis
deliveri
cell
cultur
anim
model
howev
exampl
yet
reach
clinic
trial
apart
applic
involv
human
transferrin
protein
use
sirna
particl
format
recent
report
clinic
applic
short
peptid
sirna
deliveri
applic
need
overcom
remain
obstacl
reproduc
valid
manufactur
overal
vector
addit
need
better
control
offtarget
effect
lead
toxic
peptidebas
ligand
display
vector
bound
featur
clinic
develop
near
futur
alreadi
help
gain
greater
tissu
target
specif
hope
preclin
develop
studi
publish
soon
help
move
therapi
clinic
rapidli
possibl
therapeut
approach
neuromuscular
disord
current
lead
way
clinic
develop
peptidemedi
deliveri
repeat
system
doseescal
studi
nake
pmo
omep
oligonucleotid
complet
recent
dmd
patient
doseescal
studi
plan
current
trial
review
ref
recruit
clinic
trial
treat
spinal
muscular
atrophi
underway
clinicaltrialsgov
identifi
anoth
neuromuscular
diseas
peptideconjug
pmo
like
appli
recent
concert
effort
evalu
potenti
cpp
peptid
multisystem
neuromuscular
disord
exampl
laboratori
current
involv
multicent
develop
peptidepmo
treat
dmd
base
initi
evalu
mdx
mous
model
preclin
therapeut
studi
underway
supplement
data
alreadi
publish
lead
pip
peptid
conjug
pmo
shown
excel
dystrophin
product
cardiac
muscl
tissu
previous
shown
take
nake
antisens
oligom
poorli
addit
skelet
muscl
howev
evid
induc
renal
toxic
monkey
earlier
bpmo
lead
highlight
need
caution
obtain
deeper
understand
regard
possibl
toxic
side
effect
cation
cpp
seem
like
simplic
peptid
conjug
approach
abil
appli
principl
stericblock
approach
across
broad
rang
neuromuscular
neurodegen
diseas
like
drive
clinic
develop
peptid
conjug
oligonucleotid
analogu
forward
sever
year
come
new
exampl
preclin
develop
expect
soon
sever
diseas
great
hope
one
conjug
make
clinic
near
futur
